Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Return on Capital Employed (2019 - 2025)

Serina Therapeutics' Return on Capital Employed history spans 6 years, with the latest figure at 2.37% for Q2 2024.

  • For Q2 2024, Return on Capital Employed rose 193.0% year-over-year to 2.37%; the TTM value through Jun 2024 reached 2.37%, up 193.0%, while the annual FY2023 figure was 0.67%, 168.0% down from the prior year.
  • Return on Capital Employed for Q2 2024 was 2.37% at Serina Therapeutics, up from 0.35% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 28.06% in Q3 2020 and bottomed at 53.76% in Q2 2020.
  • The 5-year median for Return on Capital Employed is 1.09% (2022), against an average of 0.32%.
  • The largest YoY upside for Return on Capital Employed was 5753bps in 2021 against a maximum downside of -2602bps in 2021.
  • A 5-year view of Return on Capital Employed shows it stood at 7.82% in 2020, then crashed by -84bps to 1.28% in 2021, then fell by -27bps to 0.94% in 2022, then tumbled by -101bps to 0.01% in 2023, then surged by 22027bps to 2.37% in 2024.
  • Per Business Quant, the three most recent readings for SER's Return on Capital Employed are 2.37% (Q2 2024), 0.35% (Q1 2024), and 0.01% (Q4 2023).